Founded in 2015 in Silicon Valley, Cipherome aims to accelerate precision medicine by simplifying complex healthcare data analysis. The company has evolved from a pharmacogenomics focus to offering the COMPASS platform, a comprehensive tool for clinical research, genomic analysis, and AI model training. Cipherome has conducted clinical validation studies with prestigious institutions and is actively commercializing its platform while contributing to healthcare data science education.
PharmacogenomicsPrecision Medicine
Technology Platform
COMPASS is a zero-code, end-to-end data analysis platform that enables extraction, cleaning, visualization, statistical testing, and AI model training on integrated clinical and genomic data without requiring programming skills.
Funding History
2
Total raised:$24M
Series A$20MUndisclosed
Seed$4MUndisclosed
Opportunities
Cipherome addresses the massive need to democratize analysis of the growing volume of clinical and genomic data.
Its no-code platform can capture market share from researchers lacking coding skills, while its pharmacogenomic algorithm has potential in the expanding precision medicine market.
Partnerships with biobanks and academic institutions provide a strong foundation for growth.
Risk Factors
Key risks include convincing researchers to adopt a new platform over flexible coding tools, potential regulatory hurdles if the DSS algorithm is used clinically, the challenges of data security and privacy, and the need for continued funding to achieve scale and profitability in a competitive market.
Competitive Landscape
Cipherome competes with traditional coding tools (Python/R), clinical analytics platforms (e.g., Tempus, Flatiron), and genomic analysis suites (e.g., DNAnexus). Its differentiation lies in its combined no-code interface, integrated clinical-genomic data handling, and foundation in validated pharmacogenomic science.
